These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23223596)

  • 1. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.
    Dimova RB; Zeremski M; Jacobson IM; Hagan H; Des Jarlais DC; Talal AH
    Clin Infect Dis; 2013 Mar; 56(6):806-16. PubMed ID: 23223596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
    Devaki P; Jencks D; Yee BE; Nguyen MH
    Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
    Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis.
    Thong VD; Poovorawan K; Tangkijvanich P; Wasitthankasem R; Vongpunsawad S; Poovorawan Y
    Intervirology; 2015; 58(6):373-81. PubMed ID: 27010195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
    Beste LA; Green PK; Ioannou GN
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.
    Lo Re V; Teal V; Localio AR; Amorosa VK; Kaplan DE; Gross R
    AIDS Behav; 2013 Jan; 17(1):94-103. PubMed ID: 22907288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
    Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
    J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients.
    Aldámiz-Echevarría T; González-García J; Von Wichmann MA; Crespo M; López-Aldeguer J; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Bellón JM; Montes M; Berenguer J
    Ann Hepatol; 2015; 14(4):464-9. PubMed ID: 26019032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
    Seeff LB; Hoofnagle JH
    Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis.
    Liu JY; Sheng YJ; Hu HD; Zhong Q; Wang J; Tong SW; Zhou Z; Zhang DZ; Hu P; Ren H
    Virol J; 2012 Sep; 9():186. PubMed ID: 22950520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
    Berenguer J; Rodríguez E; Miralles P; Von Wichmann MA; López-Aldeguer J; Mallolas J; Galindo MJ; Van Den Eynde E; Téllez MJ; Quereda C; Jou A; Sanz J; Barros C; Santos I; Pulido F; Guardiola JM; Ortega E; Rubio R; Jusdado JJ; Montes ML; Gaspar G; Esteban H; Bellón JM; González-García J;
    Clin Infect Dis; 2012 Sep; 55(5):728-36. PubMed ID: 22610932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
    Naggie S; Sulkowski MS
    Gastroenterology; 2012 May; 142(6):1324-1334.e3. PubMed ID: 22537439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience].
    Veitsman E; Shahar E; Hassoun G; Lorber M; Kramskay R; Maor C; Pollack S; Baruch Y
    Harefuah; 2012 Dec; 151(12):684-7, 721, 720. PubMed ID: 23330260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reinfection with hepatitis C virus following sustained virological response in injection drug users.
    Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1281-4. PubMed ID: 20594256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.